Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target ...

ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK), a clinical-stage biopharmaceutical company with a current market capitalization of $52 million, reported at the Hawaiian Eye and Retina 2025 ...

Chardan Capital Markets has recently initiated Mind Medicine (MindMed) Inc (MNMD) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on October 14, 2024, Leerink ...

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been assigned an average recommendation of “Buy” ...

Coya Therapeutics (NASDAQ:COYA – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently ...

Dyne Therapeutics Inc (DYN) stock saw a modest uptick, ending the day at $14.55 which represents a slight increase of $0.42 or 2.97% from the prior close of $14.13. The stock opened at $14.3 and ...

NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions, has expanded its ...

today announced that company management will participate in the following events at Chardan's 8th Annual Genetic Medicines Conference: Fireside chat on Monday, September 30, 2024, 2:30 PM - 3:00 ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...

Here’s what could be next for Gitlab.